Furthermore, it has been shown that bispecific anti-TNF-α/IL-17 antibodies may have superior efficacy and safety in treating rheumatoid arthritis (39), but this has not been demonstrated in another study involving patients with psoriasis arthritis (40). This evidence concerns the gene TNF and rheumatoid arthritis.